Orthofix Medical Inc. Derivative Instruments, Loss Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing
Orthofix Medical Inc. (OFIX) reported Derivative Instruments, Loss Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing of $3.00 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-18.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting · last filed 2015-05-18
- Orthofix Medical Inc. derivative instruments, loss recognized in income, ineffective portion and amount excluded from effectiveness testing for the quarter ending 2015-03-31 was $3.00M, a 2900.00% increase year-over-year.
- Orthofix Medical Inc. derivative instruments, loss recognized in income, ineffective portion and amount excluded from effectiveness testing for the quarter ending 2014-03-31 was $100.00K.
| Period end | Derivative Instruments, Loss Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing 3 month |
|---|---|
| 2015-03-31 | $3.00M 10-Q · filed 2015-05-18 |
| 2014-03-31 | $100.00K 10-Q · filed 2015-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |